Hematologic Oncology

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Jerald P. Radich, MD, discusses the impact of minimal residual disease in patients with acute versus chronic leukemias.

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.

Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.

Venetoclax combined with azacitidine improved overall survival versus azacitidine alone in patients with previously untreated acute myeloid leukemia.

Dimitrios Tzachanis, MD, PhD, discusses research regarding post–CAR T-cell therapy progression in lymphoma.

During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.

Topline results from the pivotal phase III FLASH trial showed that SGX301 demonstrated strong clinical activity in patients with cutaneous T-cell lymphoma.

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses the potential use of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) in patients with advanced-stage classical Hodgkin lymphoma.

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.

David S. Hong, MD, discusses the burgeoning role of multitargeted therapeutics in patients with hematologic malignancies.

The FDA has granted 2 Orphan Drug Designations to ALPN-101 for the prevention and treatment of acute graft-versus-host-disease.

David Miklos, MD, discusses the results of the phase II ZUMA-2 trial with KTE-X19 in mantle cell lymphoma.

Mohammad Maher Abdul Hay, MD, discusses the evolving role of transplant in acute lymphoblastic leukemia.

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Although acute graft-versus-host disease remains potentially fatal for patients who undergo allogeneic hematopoietic stem cell transplantation, prevention and treatment strategies for this complication are evolving.

Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses a pilot phase I/II trial with brentuximab vedotin (Adcetris) plus chemotherapy in patients with HIV-associated Hodgkin lymphoma.